Belgian Pharma Stock News

UCB (ENXTBR:UCB) is presenting new clinical and real-world data at the American Academy of Neurology Annual Meeting. The updates cover epileptic encephalopathies, prolonged seizures, and generalized myasthenia gravis. Key datasets focus on fenfluramine in Dravet and Lennox Gastaut syndromes and on zilucoplan and rozanolixizumab in myasthenia gravis. Additional findings address patient and caregiver quality of life, healthcare resource use, and treatment patterns. For investors following...

BGL BNP Paribas (ENXTBR:009789111) has released its full year 2025 results, reporting net income of €514.5 million compared to €477.9 million a year earlier. This provides investors with fresh data to reassess the stock. See our latest analysis for BGL BNP Paribas. The share price is currently €89.0, and the flat short-term share price returns sit alongside a 1-year total shareholder return of 0.00%. This suggests recent earnings news may not yet have shifted market expectations in a clear...

Solvac S.A.'s ( EBR:SOLV ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

SCR-Sibelco N.V.'s ( EBR:094426466 ) healthy profit numbers didn't contain any surprises for investors. However the...

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 3.79% amid heightened geopolitical tensions and soaring energy costs, prompting caution from the European Central Bank regarding inflation risks. In this environment of uncertainty, high-growth tech stocks in Europe are gaining attention for their potential to offer resilience and innovation-driven growth, making them an intriguing focus for investors seeking opportunities in a...

Today is shaping up negative for Banqup Group SA ( EBR:BANQ ) shareholders, with the analysts delivering a substantial...

SCR-Sibelco (ENXTBR:094426466) has put fresh numbers on the table for FY 2025, reporting first half revenue of €1.2b and net income of €78.1m, while trailing 12 month revenue is €2.3b against net income of €63.4m. Over the past year, revenue has moved from €1.1b in the first half of 2024 and €1.1b in the second half of 2024 to €1.2b in the first half of 2025. Net income shifted from €145.9m to a loss of €14.7m and then to €78.1m over the same periods. For investors, the key storyline is how...

Wondering if Solvay at €27.88 is offering good value right now, or if the best days are already priced in? This article breaks down what the current share price might be telling you. Over the short term the stock has returned 0.9% in the last 7 days and 7.1% over the past month. The year to date return sits at 2.0% and the 1 year return shows a 4.0% decline, compared with a 3 year return of 50.0% and 5 year return of 63.7%. Recent attention around Solvay has largely focused on how investors...

If you are wondering whether SCR-Sibelco is priced fairly today, you are not alone. The stock often attracts attention from investors trying to work out if they might be overpaying or missing an opportunity. Over the short term, the share price has been mixed, with a 1.3% return over the last 7 days, a 0.8% decline over 30 days, and returns of 12.7% decline year to date and 5.7% decline over the past year, extending to a 10.9% decline over five years. Recent news coverage has mainly focused...

Key Insights Significant control over Biotalys by private equity firms implies that the general public has more power...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Banqup Group SA ( EBR:BANQ ) shareholders would be excited to see that the share price has had a great month, posting a...

Key Insights Elia Group's significant private companies ownership suggests that the key decisions are influenced by...

Key Insights Significant control over Groupe Bruxelles Lambert by private companies implies that the general public has...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Umicore fair value estimate is €29.83 Umicore's €19.68 share...

It's been a sad week for Melexis NV ( EBR:MELE ), who've watched their investment drop 16% to €53.25 in the week since...

Orange Belgium (ENXTBR:OBEL) FY 2025 Earnings Snapshot Orange Belgium (ENXTBR:OBEL) has just reported its FY 2025 numbers with first half revenue of €962.7 million and basic EPS of €0.04, alongside trailing 12 month revenue of €1.96 billion and EPS of €0.61 that frame the latest run rate. The company recorded revenue of €977.5 million in the first half of 2024 and €1,016.2 million in the second half of 2024, while EPS moved from a loss of €0.20 to a profit of €0.56, before landing at €0.04 in...

Melexis NV ( EBR:MELE ) has announced that it will pay a dividend of €1.68 per share on the 21st of May. This makes the...

Key Insights Banqup Group's significant individual investors ownership suggests that the key decisions are influenced...

Despite an already strong run, DEME Group NV ( EBR:DEME ) shares have been powering on, with a gain of 26% in the last...

With a price-to-earnings (or "P/E") ratio of 13x Colruyt Group N.V. ( EBR:COLR ) may be sending bullish signals at the...

UBS Group AG has fallen below the 3% voting rights threshold in Solvay (ENXTBR:SOLB), according to recent Belgian transparency notifications. The change reflects an adjustment in UBS Group AG's shareholding that may matter for investors tracking Solvay's ownership profile. Solvay, a Belgium based chemicals group, operates in specialty materials, energy transition themes and a wide range of industrial end markets. For you as an investor, shifts in the register involving large institutions...

The Lotus Bakeries NV ( EBR:LOTB ) share price has done very well over the last month, posting an excellent gain of...